Cadila Healthcare Q4 Review – Strong Domestic Growth Mostly Offset By U.S. Decline: ICICI Direct

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Cadila Healthcare Ltd.’s Q4 revenues grew 2.5% YoY to Rs 3847 crore.

Domestic formulations grew 14.7% YoY to Rs 1023 crore.

U.S. sales fell 14.3% YoY to Rs 1509 crore. Wellness segment grew a robust 22.1% YoY to Rs 598 crore.

Emerging markets grew 45.5% YoY to Rs 250 crore.

Active pharmaceutical ingredient segment grew 19.9% YoY to Rs 140 crore. Animal health segment grew 25.2% YoY to Rs 150 crore.

Ebitda margins expanded 115 basis points YoY to 22.2% mainly due to lower other expenditure partly offset by lower gross margins.

Subsequently, Ebitda grew 8.1% YoY to Rs 855 crore.

Click on the attachment to read the full report:

ICICI Direct Cadila Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
editorpen Governmental News Finance News

Source link

Back to top button